COPE Advertising options


COPE Homepage Bottom of page Previous entry:
Next entry:
Random entry:
Search COPE:

Please donate

If COPE helps you,
please help me to continue my work.
Make a donation you can afford.


This cell surface antigen is known also as Ki-1, Ki-2, R4-4, or Ber H2 antigen. The approved gene symbol is TNFRSF8 [TNF receptor superfamily member 8] and refers to the homology of CD30 to other members of the TNF receptor superfamily.

The protein is expressed on mitogen-activated B-cells and T-cells, but not on resting lymphocytes or monocytes. CD30 is expressed also on Hodgkin and Sternberg-Reed cells of Hodgkin's lymphomas and on most Hodgkin-derived cell lines. CD30 is expressed also on a subset of non-Hodgkin's lymphomas, including Burkitt's lymphomas, and on several virus-transformed cell lines.

CD30 is a glycoprotein of 120 kDa that shows sequence homology to members of the TNF receptor superfamily. The gene encoding human CD30 maps to chromosome 1p36 (Fonatsch et al, 1992). The cDNA has been cloned by Dürkop et al (1992).

Horie et al (1996) have identified a variant of CD30, termed CD30v, that retains most of the cytoplasmic region, but lacks the extracellular and transmembrane domains. CD30v transcripts are found only in the lung, where they are expressed by alveolar macrophages, and in the HL-60 cell line after treatment with 12-O-tetradecanoyl-phorbol-13-acetate. CD30v is phosphorylated constitutively. Overexpression of CD30v induces differentiation of HL-60 cells.

The extracellular portion of CD30 is proteolytically cleaved from CD30(+) cells to produce a soluble form of the molecule (sCD30) detectable in serum (Rezaei et al, 2008). Soluble CD30 has been proposed as a marker for immune responses involving Th2 cells (Caligaris-Cappio et al, 1995; Savolainen et al, 2008).

Elevated serum levels of soluble CD30 have been found in Hodgkin's disease (Casasnovas et al, 2007; Visco et al, 2006; Gause et al, 1991), non-Hodgkin lymphomas (Purdue et al, 2009; Breen et al, 2006) anaplastic large cell lymphoma (Zinzani et al, 1998; Nadali et al, 1995), as well as some autoimmune diseases, such as systemic lupus erythematodes and rheumatoid arthritis (Ciferská et al, 2007; Savolainen et al, 2008; Rezaei et al, 2008).

A ligand for murine CD30, designated CD30L (CD30 ligand, new designation: CD153; see also: CD antigens), has been described to be a type 2 membrane protein (N-terminus inside) of 239 amino acids. Its carboxyterminal domain shows significant homology to TNF-alpha, TNF-beta, and the ligands for CD40 (see: TRAP, TNF-related activation protein) and CD27. Based on its homology with other members of the TNF ligand protein superfamily the protein is referred to also as TNFSF8 [TNF ligand superfamily member 8] (Smith et al, 1993).

Human CD30L is 72 % identical with murine CD30L at the amino acid level. The human CD30L gene maps to chromosome 9q33.

CD30L enhances proliferation of T-cells activated through engagement of CD3. It induces cell death by apoptosis in several CD30(+) lymphoma-derived cell lines. CD30L (and also CD40L, but not 4-1BB ligand) upregulate expression of CD54 by cultured Hodgkin and Reed-Sternberg cells. Enhanced CD54 surface expression by these cells is accompanied by increased shedding of surface-bound CD54 (Gruss et al, 1996).

For a virus-encoded homolog of CD30 see: viral CD30.

For other entries pertaining to cell death mechanisms see also the Apoptosis and Cell Death Dictionary section of this encyclopedia.

For additional information on CD antigens see also: CD antigens MiniCOPE Dictionary.

Copyright © 2012 by H IBELGAUFTS. All rights reserved.


See REFERENCES for entry CD30.

Click BACKLINKS to see which COPE entries contain the term CD30 .

COPE Homepage Top of Page

SUPPORT COPE | Intro | Subdictionaries | New Entries | Contribute data | COPE Credentials
# A B C D E F G H I J K L M N O P Q R S T U V W X Y Z

Please inquire. COPE is interested in contacts with corporate sponsors appreciating and committed to communication biology

              Created, developed, and maintained by Prof Dr H Ibelgaufts              
About the author of COPE
  |    Contact COPE   |    Terms & Conditions

U L T R A   P O S S E   N E M O   O B L I G A T U R